OncoSec Medical, Inc. (ONCS) Starts Presentation at LD Micro Conference

OncoSec Medical, Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy, currently in phase 2 development. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com